

Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	12 months to 31 March 2024	
Previous Reporting Period	12 months to 31 March 2023	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$195,411	Up 25%
Total Revenue	\$195,411	Up 25%
Net profit/(loss) from continuing operations	\$15,609	Up 46%
Total net profit/(loss)	\$15,609	Up 46%
Interim/Final Dividend		
Quoted Equity Securities:		
Amount per Quoted Equity Security	\$0.01100000	
Imputed amount per Quoted Equity Security	No imputation	
Record Date	19/06/2023	
Dividend Payment Date	04/07/2023	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.33	\$0.26
A brief explanation of any of the figures above necessary to enable the figures to be understood	<p>Accompanying this announcement are the Group's audited consolidated financial statements for the twelve months ended 31 March 2024. These financial statements and the full year results commentary dated 23 May 2024 provide the balance of information requirements in accordance with NZX Listing Rules and Appendix 2.</p> <p>Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).</p>	
Authority for this announcement		
Name of person authorised to make this announcement	Malcolm Tubby	
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd	
Contact phone number	+64 9 488 0232	
Contact email address	Malcolm.tubby@aftpharm.com	
Date of release through MAP	23 May 2024	

Audited financial statements accompany this announcement.